PERSONAL INFORMATION Adrian Llerena Ruiz Faculty of ... · PDF fileCurriculum vitae Adrian...

Curriculum vitae

PERSONAL INFORMATION Adrian Llerena Ruiz

WORK EXPERIENCE

April 1986–Present Lecturer-Professor (Profesor Ayudante-Profesor Titular-Catedrático)Faculty of Medicine. University of Extremadura (Spain)

Faculty of Medicine Teaching Pharmacology and Clinical Pharmacology) -

Coordinator Master Degree (EU Bologna) on Clinical Research (2005-2013) -

Coordinator Postgraduate IberoAmerican Master Degree on Clinical Pharmacology and Pharmacogenetics (2009-current)

20 PhD-Thesis Director -

Director Clinical Research Center. University Hospital 2006-current

January 2006–Present Director Clinical Research Center University HospitalExtremadura Public Health Care Services SES University University Hospital (Spain)

Clinical Research and Clinical Trials -

Clinical Pharmacogenetics -

Clinical Pharmacology -

EDUCATION AND TRAINING

October 1984–December 1988 MD (Spanish Medicine and Surgery) PhDUniversity of Extremadura Medical School (Spain)

Master Degree: Liver Pathology

PhD Thesis: CYP2D6 Pharmacogenetics in Healthy volunteers

June 1989–February 1992 Post Doctoral Training - Swedish Medical LicenceKarolinska Institute. Huddinge University Hospital- Dpt Clinical Pharmacology (Sweden)

Clinical Pharmacology - Pharmacogenetics - Psychopharmacology

July 1992–September 1992 Visiting ScientistKarolinska Institute. Huddinge University Hospital- Dpt Clinical Pharmacology

Clinical Pharmacology - Pharmacogenetics - Psychopharmacology

January 2004–July 2005 Visiting SchoolarUCLA University of California Los Angeles (United States)

Center for Pharmacogenetics and Clinical Pharmacology

ADDITIONAL INFORMATION

Expertise - Medical Doctor - Clinical Pharmacology

- Clinical Pharmacogenetics and Pharmacogenomics

- Clinical Research and Clinical Trials

- Clinical Psychopharmacology

- Population Pharmacogenetics

22/11/17 © European Union, 2002-2017 | http://europass.cedefop.europa.eu / 23

Curriculum vitae Adrian Llerena Ruiz

Publications (PubMed; n=193)

1: Arellano AL, Martin-Subero M, Monerris M, LLerena A, Farré M, Montané E.

Multiple adverse drug reactions and genetic polymorphism testing: A case report

with negative result. Medicine (Baltimore). 2017 Nov;96(45):e8505. doi:

10.1097/MD.0000000000008505. PubMed PMID: 29137046.

2: Magalhães P, Alves G, Llerena A, Falcão A. Therapeutic Drug Monitoring of

Fluoxetine, Norfluoxetine and Paroxetine: A New Tool Based on Microextraction by

Packed Sorbent Coupled to Liquid Chromatography. J Anal Toxicol. 2017 Sep

1;41(7):631-638. doi: 10.1093/jat/bkx043. PubMed PMID: 28873974.

3: de Andrés F, Sosa-Macías M, Ramos BPL, Naranjo MG, LLerena A. CYP450

Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where

to from Here for Global Precision Medicine? OMICS. 2017 Sep;21(9):509-519. doi:

10.1089/omi.2017.0101. Epub 2017 Sep 5. PubMed PMID: 28873029.

4: Bioque M, García-Portilla MAP, García-Rizo C, Cabrera B, Lobo A,

González-Pinto A, Díaz-Caneja CM, Corripio I, Vieta E, Castro-Fornieles J, Bobes

J, Gutiérrez-Fraile M, Rodriguez-Jimenez R, Mezquida G, Llerena A, Saiz-Ruiz J,

Bernardo M; PEPs GROUP. Evolution of metabolic risk factors over a two-year

period in a cohort of first episodes of psychosis. Schizophr Res. 2017 Jun 26.

pii: S0920-9964(17)30370-5. doi: 10.1016/j.schres.2017.06.032. [Epub ahead of

print] PubMed PMID: 28663026.

5: Jukić MM, Opel N, Ström J, Carrillo-Roa T, Miksys S, Novalen M, Renblom A, Sim

SC, Peñas-Lledó EM, Courtet P, Llerena A, Baune BT, de Quervain DJ,

Papassotiropoulos A, Tyndale RF, Binder EB, Dannlowski U, Ingelman-Sundberg M.

Elevated CYP2C19 expression is associated with depressive symptoms and

hippocampal homeostasis impairment. Mol Psychiatry. 2017 Aug;22(8):1224. doi:

10.1038/mp.2017.93. Epub 2017 Apr 18. PubMed PMID: 28416806.

6: Mas S, Gassó P, Torra M, Bioque M, Lobo A, González-Pinto A, Olmeda MS,

Corripio I, Vieta E, Castro-Fornieles J, Rodriguez-Jimenez R, Bobes J, Usall J,

Llerena A, Saiz-Ruiz J, Bernardo M, Lafuente A, PEPs Group. Intuitive

pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated

from genotype in a cohort of first episode psychosis patients. Eur

Neuropsychopharmacol. 2017 Jul;27(7):647-656. doi:

10.1016/j.euroneuro.2017.03.012. Epub 2017 Apr 5. PubMed PMID: 28389049.

7: Fricke-Galindo I, LLerena A, López-López M. An update on HLA alleles

associated with adverse drug reactions. Drug Metab Pers Ther. 2017 May

24;32(2):73-87. doi: 10.1515/dmpt-2016-0025. Review. PubMed PMID: 28315856.

8: Dorado P, González I, Naranjo ME, de Andrés F, Peñas-Lledó EM, Calzadilla LR,

LLerena A. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is

Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism. OMICS. 2017

Jan;21(1):17-26. doi: 10.1089/omi.2016.0166. PubMed PMID: 28271978.

9: Xie T, Stathopoulou MG, de Andrés F, Siest G, Murray H, Martin M, Cobaleda J,

Delgado A, Lamont J, Peñas-LIedó E, LLerena A, Visvikis-Siest S. VEGF-related

polymorphisms identified by GWAS and risk for major depression. Transl

Psychiatry. 2017 Mar 7;7(3):e1055. doi: 10.1038/tp.2017.36. PubMed PMID:

28267147; PubMed Central PMCID: PMC5416679.

10: Yılmaz ŞG, Llerena A, De Andrés F, Karakaş Ü, Gündoğar H, Erciyas K, Kimyon

S, Mete A, Güngör K, Özdemir V. Water pipe (Shisha, Hookah, Arghile) Smoking and



Secondhand Tobacco Smoke Effects on CYP1A2 and CYP2A6 Phenotypes as Measured by

Caffeine Urine Test. OMICS. 2017 Mar;21(3):177-182. doi: 10.1089/omi.2016.0188.

Epub 2017 Feb 16. PubMed PMID: 28253085.

11: Magalhães P, De Andrés F, Falcão A, LLerena A, Alves G. Can the CEIBA

Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug

Interaction Studies? J Pharm Pharm Sci. 2016 Oct - Dec;19(4):520-529. doi:

10.18433/J3D313. PubMed PMID: 28057170.

12: Peiró AM, Margarit C, LLerena A. What is the future of pharmacogenomics in

pain management? Pharmacogenomics. 2017 Jan;18(2):101-103. doi:

10.2217/pgs-2016-0173. Epub 2016 Dec 19. PubMed PMID: 27992298.

13: Jukić MM, Opel N, Ström J, Carrillo-Roa T, Miksys S, Novalen M, Renblom A,

Sim SC, Peñas-Lledó EM, Courtet P, Llerena A, Baune BT, de Quervain DJ,

Papassotiropoulos A, Tyndale RF, Binder EB, Dannlowski U, Ingelman-Sundberg M.

Elevated CYP2C19 expression is associated with depressive symptoms and

hippocampal homeostasis impairment. Mol Psychiatry. 2017 Aug;22(8):1155-1163.

doi: 10.1038/mp.2016.204. Epub 2016 Nov 29. Erratum in: Mol Psychiatry. 2017

Aug;22(8):1224. PubMed PMID: 27895323.

14: De Andrés F, Terán S, Hernández F, Terán E, LLerena A. To Genotype or

Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme

Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.

OMICS. 2016 Dec;20(12):699-710. Epub 2016 Nov 16. PubMed PMID: 27849442.

15: Sánchez-Pozos K, Rivera-Santiago C, García-Rodríguez MH, Ortiz-López MG,

Peña-Espinoza BI, Granados-Silvestre ML, Llerena A, Menjívar M. Genetic

variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico.

Pharmacogenomics. 2016 Oct 28. [Epub ahead of print] PubMed PMID: 27790940.

16: Sosa-Macías M, Teran E, Waters W, Fors MM, Altamirano C, Jung-Cook H,

Galaviz-Hernández C, López-López M, Remírez D, Moya GE, Hernández F, Fariñas H,

Ramírez R, Céspedes-Garro C, Tarazona-Santos E, LLerena A. Pharmacogenetics and

ethnicity: relevance for clinical implementation, clinical trials,

pharmacovigilance and drug regulation in Latin America. Pharmacogenomics. 2016

Oct 28. [Epub ahead of print] PubMed PMID: 27790935.

17: Fricke-Galindo I, Ortega-Vázquez A, Monroy-Jaramillo N, Dorado P, Jung-Cook

H, Peñas-Lledó E, LLerena A, López-López M. Allele and genotype frequencies of

genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy

volunteers. Pharmacogenomics. 2016 Oct 28. [Epub ahead of print] PubMed PMID:

27790929.

18: de Andrés F, LLerena A. Simultaneous Determination of Cytochrome P450

Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach. Curr

Pharm Biotechnol. 2016;17(13):1159-1180. Review. PubMed PMID: 27677273.

19: Peiró AM, Planelles B, Juhasz G, Bagdy G, Libert F, Eschalier A, Busserolles

J, Sperlagh B, Llerena A. Pharmacogenomics in pain treatment. Drug Metab Pers

Ther. 2016 Sep 1;31(3):131-42. doi: 10.1515/dmpt-2016-0005. Review. PubMed PMID:

27662648.

20: Céspedes-Garro C, Naranjo MG, Rodrigues-Soares F, LLerena A, Duconge J,

Montané-Jaime LK, Roblejo H, Fariñas H, Campos ML, Ramírez R, Serrano V,

Villagrán CI, Peñas-LLedó EM. Pharmacogenetic research activity in Central

America and the Caribbean: a systematic review. Pharmacogenomics. 2016



Oct;17(15):1707-1724. Epub 2016 Sep 16. Review. PubMed PMID: 27633613; PubMed

Central PMCID: PMC5558513.

21: Mas S, Gassó P, Lafuente A, Bioque M, Lobo A, Gonzàlez-Pinto A, Olmeda MS,

Corripio I, Llerena A, Cabrera B, Saiz-Ruiz J, Bernardo M; PEPs GROUP.

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a

first episode psychosis cohort: role of dopamine, serotonin and glutamate

candidate genes. Pharmacogenomics J. 2016 Oct;16(5):439-45. doi:

10.1038/tpj.2016.44. Epub 2016 Jun 7. PubMed PMID: 27272046.

22: Naranjo ME, de Andrés F, Delgado A, Cobaleda J, Peñas-Lledó EM, LLerena A.

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about

their misclassification in worldwide population studies. Pharmacogenomics J. 2016

Oct;16(5):485-90. doi: 10.1038/tpj.2016.47. Epub 2016 Jun 7. PubMed PMID:

27272044.

23: Saygılı Eİ, Abou-Zeid AH, Akkın SM, Aklillu E, Barlas İÖ, Borda-Rodriguez A,

Boschele FA, Çetin Z, Coşkun E, Coşkun Y, Dağlı G, Dai TU, Dandara C, Dereli T,

Elbeyli L, Endrenyi L, Eyigün CP, Georgakilas A, Günbulut B, Güngör K, Güzelbey

A, Hekim C, Huzair F, Kimyon S, Karakaş Ü, Lin B, LLerena A, Masimirembwa C,

McNally R, Mete A, Sancar P, Srivastava S, Steuten LM, Tanrıöver O, Tyfield D,

Töre Vİ, Vuruşkan D, Wang W, Warnich L, Wonkam A, Yıldırım YZ, Yılmaz İ, Sınav A,

Hekim N. An Open Letter in Support of Transformative Biotechnology and Social

Innovation: SANKO University Innovation Summit in Medicine and Integrative

Biology, Gaziantep, Turkey, May 5-7, 2016. OMICS. 2016 Apr;20(4):259-62. doi:

10.1089/omi.2016.0038. PubMed PMID: 27093110.

24: Moya G, Dorado P, Ferreiro V, Naranjo MEG, Peñas-Lledó EM, LLerena A. High

frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish

population from Argentina. Pharmacogenomics J. 2017 Jul;17(4):378-381. doi:

10.1038/tpj.2016.27. Epub 2016 Apr 12. PubMed PMID: 27068265.

25: González-Vacarezza N, Alonso I, Arroyo G, Martínez J, De Andrés F, LLerena A,

Estévez-Carrizo F. Predictive biomarkers candidates for patients with metastatic

colorectal cancer treated with bevacizumab-containing regimen. Drug Metab Pers

Ther. 2016 Jun 1;31(2):83-90. doi: 10.1515/dmpt-2015-0027. Review. PubMed PMID:

26974145.

26: Maroñas O, Latorre A, Dopazo J, Pirmohamed M, Rodríguez-Antona C, Siest G,

Carracedo Á, LLerena A. Progress in pharmacogenetics: consortiums and new

strategies. Drug Metab Pers Ther. 2016 Mar;31(1):17-23. doi:

10.1515/dmpt-2015-0039. Review. PubMed PMID: 26913460.

27: Fricke-Galindo I, Jung-Cook H, LLerena A, López-López M. Interethnic

variability of pharmacogenetic biomarkers in Mexican healthy volunteers: a report

from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics).

Drug Metab Pers Ther. 2016 Jun 1;31(2):61-81. doi: 10.1515/dmpt-2015-0030.

Review. PubMed PMID: 26812836.

28: Shah RR, Gaedigk A, LLerena A, Eichelbaum M, Stingl J, Smith RL. CYP450

genotype and pharmacogenetic association studies: a critical appraisal.

Pharmacogenomics. 2016 Feb;17(3):259-75. doi: 10.2217/pgs.15.172. Epub 2016 Jan

18. PubMed PMID: 26780308.

29: de Andrés F, Terán S, Bovera M, Fariñas H, Terán E, LLerena A. Multiplex

Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling



Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6

Activities Using a Cocktail Approach. OMICS. 2016 Feb;20(2):88-96. doi:

10.1089/omi.2015.0131. Epub 2015 Nov 24. PubMed PMID: 26600202.

30: Céspedes-Garro C, Fricke-Galindo I, Naranjo ME, Rodrigues-Soares F, Fariñas

H, de Andrés F, López-López M, Peñas-Lledó EM, LLerena A. Worldwide interethnic

variability and geographical distribution of CYP2C9 genotypes and phenotypes.

Expert Opin Drug Metab Toxicol. 2015;11(12):1893-905. doi:

10.1517/17425255.2015.1111871. Epub 2015 Nov 23. Review. PubMed PMID: 26595139.

31: Bioque M, Llerena A, Cabrera B, Mezquida G, Lobo A, González-Pinto A,

Díaz-Caneja CM, Corripio I, Aguilar EJ, Bulbena A, Castro-Fornieles J, Vieta E,

Lafuente A, Mas S, Parellada M, Saiz-Ruiz J, Cuesta MJ, Bernardo M; PEPs GROUP. A

Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological

Interventions and Safety Profiles in the PEPs Project. Int J

Neuropsychopharmacol. 2016 Mar 31;19(4). pii: pyv121. doi: 10.1093/ijnp/pyv121.

Print 2016 Apr. PubMed PMID: 26506856; PubMed Central PMCID: PMC4851267.

32: Fricke-Galindo I, Céspedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado

Á, de Andrés F, López-López M, Peñas-Lledó E, LLerena A. Interethnic variation of

CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes

across world populations. Pharmacogenomics J. 2016 Apr;16(2):113-23. doi:

10.1038/tpj.2015.70. Epub 2015 Oct 27. Review. PubMed PMID: 26503820.

33: Bedada W, de Andrés F, Engidawork E, Pohanka A, Beck O, Bertilsson L, Llerena

A, Aklillu E. The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme

Activity in Humans. J Clin Psychopharmacol. 2015 Dec;35(6):694-9. doi:

10.1097/JCP.0000000000000413. PubMed PMID: 26444948.

34: LLerena A, Peñas-Lledó EM. Metabolic phenotype prediction from genotyping

data: a bottleneck for the implementation of pharmacogenetics in drug development

and clinical practice. Drug Metab Pers Ther. 2015 Sep;30(3):143-5. doi:

10.1515/dmpt-2015-0025. PubMed PMID: 26353178.

35: Dove ES, Barlas IÖ, Birch K, Boehme C, Borda-Rodriguez A, Byne WM, Chaverneff

F, Coşkun Y, Dahl ML, Dereli T, Diwakar S, Elbeyli L, Endrenyi L, Eroğlu-Kesim B,

Ferguson LR, Güngör K, Gürsoy U, Hekim N, Huzair F, Kaushik K, Kickbusch I,

Kıroğlu O, Kolker E, Könönen E, Lin B, Llerena A, Malhan F, Nair B, Patrinos GP,

Şardaş S, Sert Ö, Srivastava S, Steuten LM, Toraman C, Vayena E, Wang W, Warnich

L, Özdemir V. An Appeal to the Global Health Community for a Tripartite

Innovation: An "Essential Diagnostics List," "Health in All Policies," and

"See-Through 21(st) Century Science and Ethics". OMICS. 2015 Aug;19(8):435-42.

doi: 10.1089/omi.2015.0075. Epub 2015 Jul 10. PubMed PMID: 26161545.

36: Ortega-Vázquez A, Dorado P, Fricke-Galindo I, Jung-Cook H, Monroy-Jaramillo

N, Martínez-Juárez IE, Familiar-López I, Peñas-Lledó E, LLerena A, López-López M.

CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations

in Mexican-Mestizo patients with epilepsy. Pharmacogenomics J. 2016

Jun;16(3):286-92. doi: 10.1038/tpj.2015.45. Epub 2015 Jun 30. PubMed PMID:

26122019.

37: Mitropoulos K, Al Jaibeji H, Forero DA, Laissue P, Wonkam A, Lopez-Correa C,

Mohamed Z, Chantratita W, Lee MT, Llerena A, Brand A, Ali BR, Patrinos GP.

Success stories in genomic medicine from resource-limited countries. Hum

Genomics. 2015 Jun 18;9:11. doi: 10.1186/s40246-015-0033-3. PubMed PMID:




38: LLerena A. Population pharmacogenetics and global health. Drug Metab Pers

Ther. 2015 Jun;30(2):73-4. doi: 10.1515/dmdi-2015-0014. PubMed PMID: 25996490.

39: Fricke-Galindo I, Jung-Cook H, LLerena A, López-López M. Pharmacogenetics of

adverse reactions to antiepileptic drugs. Neurologia. 2015 May 11. pii:

S0213-4853(15)00056-0. doi: 10.1016/j.nrl.2015.03.005. [Epub ahead of print]

English, Spanish. PubMed PMID: 25976948.

40: Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS,

Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle

KE, Gaedigk A; Clinical Pharmacogenetics Implementation Consortium. Clinical

Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and

CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin

Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29.

Review. PubMed PMID: 25974703; PubMed Central PMCID: PMC4512908.

41: Özdemir V, Kılıç H, Yıldırım A, Vayena E, Dove ES, Güngör K, LLerena A,

Şardaş S. A code of ethics for ethicists: what would Pierre Bourdieu say? "Do not

misuse social capital in the age of consortia ethics". Am J Bioeth.

2015;15(5):64-7. doi: 10.1080/15265161.2015.1021976. PubMed PMID: 25970399.

42: Perez-Paramo YX, Hernandez-Cabrera F, Dorado P, Llerena A, Muñoz-Jimenez S,

Ortiz-Lopez R, Rojas-Martinez A. Interethnic relationships of CYP2D6 variants in

native and Mestizo populations sharing the same ecosystem. Pharmacogenomics.

2015;16(7):703-12. doi: 10.2217/pgs.15.24. Epub 2015 May 5. PubMed PMID:

25941923.

43: Sosa-Macias M, Moya GE, LLerena A, Ramírez R, Terán E, Peñas-LLedó EM,

Tarazona-Santos E, Galaviz-Hernández C, Céspedes-Garro C, Acosta H. Population

pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014).

Pharmacogenomics. 2015;16(7):673-6. doi: 10.2217/pgs.15.32. Epub 2015 May 1.

PubMed PMID: 25929854.

44: Céspedes-Garro C, Jiménez-Arce G, Naranjo ME, Barrantes R, Llerena A;

CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics &

Pharmacogenomics RIBEF. Ethnic background and CYP2D6 genetic polymorphisms in

Costa Ricans. Rev Biol Trop. 2014 Dec;62(4):1659-71. PubMed PMID: 25720195.

45: Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A,

Ingelman-Sundberg M, Papaluca-Amati M. Pharmacogenomic information in drug

labels: European Medicines Agency perspective. Pharmacogenomics J. 2015

Jun;15(3):201-10. doi: 10.1038/tpj.2014.86. Epub 2015 Feb 24. Review. PubMed

PMID: 25707393.

46: Peñas-Lledó E, Guillaume S, Delgado A, Naranjo ME, Jaussent I, LLerena A,

Courtet P. ABCB1 gene polymorphisms and violent suicide attempt among survivors.

J Psychiatr Res. 2015 Feb;61:52-6. doi: 10.1016/j.jpsychires.2014.12.005. Epub

2014 Dec 15. PubMed PMID: 25543520.

47: Magalhães P, Alves G, Rodrigues M, LLerena A, Falcão A. First MEPS/HPLC assay

for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in

human plasma. Bioanalysis. 2014;6(22):3025-38. doi: 10.4155/bio.14.222. PubMed

PMID: 25496255.

48: López-López M, Peñas-Lledó E, Dorado P, Ortega A, Corona T, Ochoa A, Yescas

P, Alonso E, LLerena A. CYP2D6 genetic polymorphisms in Southern Mexican Mayan



Lacandones and Mestizos from Chiapas. Pharmacogenomics. 2014;15(15):1859-65. doi:

10.2217/pgs.14.139. PubMed PMID: 25495408.

49: Céspedes-Garro C, Naranjo ME, Ramírez R, Serrano V, Fariñas H, Barrantes R,

LLerena A; CEIBA Consortium of the Ibero-American Network of Pharmacogenetics and

Pharmacogenomics RIBEF. Pharmacogenetics in Central American healthy volunteers:

interethnic variability. Drug Metab Pers Ther. 2015 Mar;30(1):19-31. Review.


50: Blasco-Fontecilla H, Peñas-Lledó E, Vaquero-Lorenzo C, Dorado P, Saiz-Ruiz J,

Llerena A, Baca-García E. CYP2D6 polymorphism and mental and personality

disorders in suicide attempters. J Pers Disord. 2014 Dec;28(6):873-83. doi:

10.1521/pedi_2012_26_080. PubMed PMID: 25437930.

51: Apellániz-Ruiz M, Inglada-Pérez L, Naranjo ME, Sánchez L, Mancikova V,

Currás-Freixes M, de Cubas AA, Comino-Méndez I, Triki S, Rebai A, Rasool M, Moya

G, Grazina M, Opocher G, Cascón A, Taboada-Echalar P, Ingelman-Sundberg M,

Carracedo A, Robledo M, Llerena A, Rodríguez-Antona C. High frequency and founder

effect of the CYP3A4*20 loss-of-function allele in the Spanish population

classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics J. 2015

Jun;15(3):288-92. doi: 10.1038/tpj.2014.67. Epub 2014 Nov 4. PubMed PMID:

25348618.

52: LLerena A, Naranjo ME, Rodrigues-Soares F, Penas-LLedó EM, Fariñas H,

Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and

measured metabolic phenotypes across world populations. Expert Opin Drug Metab

Toxicol. 2014 Nov;10(11):1569-83. doi: 10.1517/17425255.2014.964204. Review.


53: Dorado P, Gallego A, Peñas-LLedó E, Terán E, LLerena A. Relationship between

the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy

Ecuadorian volunteers. Pharmacogenomics. 2014 Aug;15(11):1417-21. doi:

10.2217/pgs.14.85. PubMed PMID: 25303293.

54: Peñas-Lledó E, Guillaume S, Naranjo ME, Delgado A, Jaussent I,

Blasco-Fontecilla H, Courtet P, LLerena A. A combined high CYP2D6-CYP2C19

metabolic capacity is associated with the severity of suicide attempt as measured

by objective circumstances. Pharmacogenomics J. 2015 Apr;15(2):172-6. doi:

10.1038/tpj.2014.42. Epub 2014 Aug 12. PubMed PMID: 25113522.

55: Magalhães P, Alves G, LLerena A, Falcão A. Clinical drug-drug interactions:

focus on venlafaxine. Drug Metab Pers Ther. 2015 Mar;30(1):3-17. doi:

10.1515/dmdi-2014-0011. Review. PubMed PMID: 24964257.

56: Hekim N, Coşkun Y, Sınav A, Abou-Zeid AH, Ağırbaşlı M, Akintola SO,

Aynacıoğlu Ş, Bayram M, Bragazzi NL, Dandara C, Dereli T, Dove ES, Elbeyli L,

Endrenyi L, Erciyas K, Faris J, Ferguson LR, Göğüş F, Güngör K, Gürsoy M, Gürsoy

UK, Karaömerlioğlu MA, Kickbusch I, Kılıç T, Kılınç M, Kocagöz T, Lin B, LLerena

A, Manolopoulos VG, Nair B, Özkan B, Pang T, Sardaş Ş, Srivastava S, Toraman C,

Üstün K, Warnich L, Wonkam A, Yakıcıer MC, Yaşar Ü, Özdemir V. Translating

biotechnology to knowledge-based innovation, peace, and development? Deploy a

Science Peace Corps--an open letter to world leaders. OMICS. 2014

Jul;18(7):415-20. doi: 10.1089/omi.2014.0079. Epub 2014 Jun 23. Review. PubMed

PMID: 24955641; PubMed Central PMCID: PMC4086476.

57: Penchaszadeh VB, Rojas-Martinez A, Llerena A. A tribute to josé maría



("chema") cantú. Genet Mol Biol. 2014 Mar;37(1 Suppl):310-4. PubMed PMID:


58: Ozdemir V, Endrenyi L, Aynacıoğlu S, Bragazzi NL, Dandara C, Dove ES,

Ferguson LR, Geraci CJ, Hafen E, Kesim BE, Kolker E, Lee EJ, Llerena A, Nacak M,

Shimoda K, Someya T, Srivastava S, Tomlinson B, Vayena E, Warnich L, Yaşar U.

Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible

Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim

Association for Clinical Pharmacogenetics). OMICS. 2014 Apr;18(4):211-21. doi:

10.1089/omi.2014.0029. Epub 2014 Mar 20. PubMed PMID: 24649998; PubMed Central

PMCID: PMC3976589.

59: de Andrés F, Sosa-Macías M, Llerena A. A rapid and simple LC-MS/MS method for

the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4

hydroxylation capacity. Bioanalysis. 2014 Mar;6(5):683-96. doi:

10.4155/bio.14.20. PubMed PMID: 24620810.

60: Magalhães P, Alves G, Llerena A, Falcão A. Venlafaxine pharmacokinetics

focused on drug metabolism and potential biomarkers. Drug Metabol Drug Interact.

2014;29(3):129-41. doi: 10.1515/dmdi-2013-0053. Review. PubMed PMID: 24607919.

61: López-Torres E, Süveges A, Peñas-LLedó EM, Doña A, Dorado P, LLerena A,

Berecz R. Liver enzyme abnormalities during antipsychotic treatment: a case

report of risperidone-associated hepatotoxicity. Drug Metabol Drug Interact.

2014;29(2):123-6. doi: 10.1515/dmdi-2013-0064. PubMed PMID: 24598833.

62: Lazalde-Ramos BP, Martínez-Fierro Mde L, Galaviz-Hernández C, Garza-Veloz I,

Naranjo ME, Sosa-Macías M, Llerena A. CYP2D6 gene polymorphisms and predicted

phenotypes in eight indigenous groups from northwestern Mexico. Pharmacogenomics.

2014 Feb;15(3):339-48. doi: 10.2217/pgs.13.203. PubMed PMID: 24533713.

63: Dorado P, Peñas-Lledo EM, Llerena A. Research Highlights: novel CYP2C9

genetic polymorphisms and assessment of their impact on hydroxylation capacity.

Pharmacogenomics. 2014 Feb;15(3):261-4. doi: 10.2217/pgs.13.243. PubMed PMID:

24533705.

64: Kolker E, Özdemir V, Martens L, Hancock W, Anderson G, Anderson N, Aynacioglu

S, Baranova A, Campagna SR, Chen R, Choiniere J, Dearth SP, Feng WC, Ferguson L,

Fox G, Frishman D, Grossman R, Heath A, Higdon R, Hutz MH, Janko I, Jiang L,

Joshi S, Kel A, Kemnitz JW, Kohane IS, Kolker N, Lancet D, Lee E, Li W, Lisitsa

A, Llerena A, Macnealy-Koch C, Marshall JC, Masuzzo P, May A, Mias G, Monroe M,

Montague E, Mooney S, Nesvizhskii A, Noronha S, Omenn G, Rajasimha H, Ramamoorthy

P, Sheehan J, Smarr L, Smith CV, Smith T, Snyder M, Rapole S, Srivastava S,

Stanberry L, Stewart E, Toppo S, Uetz P, Verheggen K, Voy BH, Warnich L, Wilhelm

SW, Yandl G. Toward more transparent and reproducible omics studies through a

common metadata checklist and data publications. OMICS. 2014 Jan;18(1):10-4. doi:

10.1089/omi.2013.0149. PubMed PMID: 24456465; PubMed Central PMCID: PMC3903324.

65: Özdemir V, Kolker E, Hotez PJ, Mohin S, Prainsack B, Wynne B, Vayena E,

Coşkun Y, Dereli T, Huzair F, Borda-Rodriguez A, Bragazzi NL, Faris J, Ramesar R,

Wonkam A, Dandara C, Nair B, Llerena A, Kılıç K, Jain R, Reddy PJ, Gollapalli K,

Srivastava S, Kickbusch I. Ready to put metadata on the post-2015 development

agenda? Linking data publications to responsible innovation and science

diplomacy. OMICS. 2014 Jan;18(1):1-9. doi: 10.1089/omi.2013.0170. Review. PubMed

PMID: 24456464.



66: Jaramillo NM, Galindo IF, Vázquez AO, Cook HJ, LLerena A, López ML.

Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and

clinical response. Drug Metabol Drug Interact. 2014;29(2):67-79. doi:


67: Kolker E, Özdemir V, Martens L, Hancock W, Anderson G, Anderson N, Aynacioglu

S, Baranova A, Campagna SR, Chen R, Choiniere J, Dearth SP, Feng WC, Ferguson L,

Fox G, Frishman D, Grossman R, Heath A, Higdon R, Hutz MH, Janko I, Jiang L,

Joshi S, Kel A, Kemnitz JW, Kohane IS, Kolker N, Lancet D, Lee E, Li W, Lisitsa

A, Llerena A, MacNealy-Koch C, Marshall JC, Masuzzo P, May A, Mias G, Monroe M,

Montague E, Mooney S, Nesvizhskii A, Noronha S, Omenn G, Rajasimha H, Ramamoorthy

P, Sheehan J, Smarr L, Smith CV, Smith T, Snyder M, Rapole S, Srivastava S,

Stanberry L, Stewart E, Toppo S, Uetz P, Verheggen K, Voy BH, Warnich L, Wilhelm

SW, Yandl G. Toward More Transparent and Reproducible Omics Studies Through a

Common Metadata Checklist and Data Publications. Big Data. 2013 Dec;1(4):196-201.

doi: 10.1089/big.2013.0039. PubMed PMID: 27447251.

68: Llerena A, Dorado P, Ramírez R, Calzadilla LR, Peñas-Lledó E, Álvarez M,

Naranjo ME, González I, Pérez B; CEIBA Consortium of Ibero–American Network of

Pharmacogenetics & Pharmacogenomics RIBEF. CYP2D6 -1584C>G promoter polymorphism

and debrisoquine ultrarapid hydroxylation in healthy volunteers.

Pharmacogenomics. 2013 Dec;14(16):1973-7. doi: 10.2217/pgs.13.181. PubMed PMID:

24279852.

69: Peñas-Lledó EM, Llerena A. CYP2D6 genetic polymorphism and psychiatry

patients' hospitalization period. Biomark Med. 2013 Dec;7(6):915-6. doi:

10.2217/bmm.13.108. PubMed PMID: 24266825.

70: Sosa-Macías M, Llerena A. Cytochrome P450 genetic polymorphisms of Mexican

indigenous populations. Drug Metabol Drug Interact. 2013;28(4):193-208. doi:


71: Cuautle-Rodríguez P, Llerena A, Molina-Guarneros J. Present status and

perspective of pharmacogenetics in Mexico. Drug Metabol Drug Interact.

2014;29(1):37-45. doi: 10.1515/dmdi-2013-0019. Review. PubMed PMID: 24129103.

72: Peñas-Lledó EM, Llerena A. CYP2D6 variation, behaviour and psychopathology:

implications for pharmacogenomics-guided clinical trials. Br J Clin Pharmacol.

2014 Apr;77(4):673-83. doi: 10.1111/bcp.12227. Review. PubMed PMID: 24033670;

PubMed Central PMCID: PMC3971983.

73: Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo

C, Fernandez-Piqueras J, Llerena A, Abad-Santos F, Baca-García E, Dal-Ré R, Ayuso

C; Spanish Consortium of Pharmacogenetics Research in Schizophrenia. CYP2D6 poor

metabolizer status might be associated with better response to risperidone

treatment. Pharmacogenet Genomics. 2013 Nov;23(11):627-30. doi:

10.1097/FPC.0b013e3283659a94. PubMed PMID: 24026091.

74: Llerena A, Alvarez M, Dorado P, González I, Peñas-LLedó E, Pérez B, Cobaleda

J, Calzadilla LR. Interethnic differences in the relevance of CYP2C9 genotype and

environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain.

Pharmacogenomics J. 2014 Jun;14(3):229-34. doi: 10.1038/tpj.2013.28. Epub 2013

Aug 20. PubMed PMID: 23959274.

75: de Andrés F, Sosa-Macías M, Lazalde-Ramos BP, Naranjo ME, Tarazona-Santos E,

Llerena A; CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics



and Pharmacogenomics RIBEFa. Evaluation of drug-metabolizing enzyme hydroxylation

phenotypes in Hispanic populations: the CEIBA cocktail. Drug Metabol Drug

Interact. 2013;28(3):135-46. doi: 10.1515/dmdi-2013-0020. Review. PubMed PMID:

23787463.

76: González-Vacarezza N, Dorado P, Peñas-Lledó EM, Fariñas H, Estévez-Carrizo

FE, Llerena A. MDR-1 genotypes and quetiapine pharmacokinetics in healthy

volunteers. Drug Metabol Drug Interact. 2013;28(3):163-6. doi:

10.1515/dmdi-2013-0008. PubMed PMID: 23740681.

77: Stathopoulou MG, Monteiro P, Shahabi P, Peñas-Lledó E, El Shamieh S, Silva

Santos L, Thilly N, Siest G, Llerena A, Visvikis-Siest S. Newly identified

synergy between clopidogrel and calcium-channel blockers for blood pressure

regulation possibly involves CYP2C19 rs4244285. Int J Cardiol. 2013 Oct

3;168(3):3057-8. doi: 10.1016/j.ijcard.2013.04.097. Epub 2013 May 3. PubMed PMID:

23643422.

78: Dorado P, Peñas-Lledó E, Llerena A. Highlights from the latest articles in

CYP2D6 activity and breast cancer outcomes during treatment with tamoxifen.

Pharmacogenomics. 2013 Apr;14(6):604-6. doi: 10.2217/pgs.13.42. PubMed PMID:

23570463.

79: Espinosa García J, Martell Claros N, Llerena Ruiz A, Fernández Bergés Gurrea

D. [Pharmacological compliance in the treatment of arterial hypertension. A

review of studies published between 1975 and 2011]. Semergen. 2012

Jul-Aug;38(5):292-300. doi: 10.1016/j.semerg.2012.01.001. Epub 2012 Apr 11.

Review. Spanish. PubMed PMID: 23544776.

80: Peñas-Lledó EM, Naranjo ME, Llerena A. Impact of cytochrome P450 genes on

suicide attempt and risk. Eur Arch Psychiatry Clin Neurosci. 2013

Dec;263(8):703-4. doi: 10.1007/s00406-013-0402-7. Epub 2013 Mar 16. PubMed PMID:

23504002.

81: Vidal-Perez R, Otero-Raviña F, Lado-López M, Turrado-Turrado V,

Rodríguez-Moldes E, Gómez-Vázquez JL, de Frutos-de Marcos C, de Blas-Abad P,

Besada-Gesto R, Gonzalez-Juanatey JR; BARBANZA Investigators. The change in the

atrial fibrillation type as a prognosis marker in a community study: long-term

data from AFBAR (Atrial Fibrillation in the BARbanza) study. Int J Cardiol. 2013

Oct 3;168(3):2146-52. doi: 10.1016/j.ijcard.2013.01.261. Epub 2013 Feb 26. PubMed

PMID: 23452888.

82: Llerena A. Clinical pharmacology of drug metabolism and drug interactions:

clinical, interethnical and regulatory aspects. Drug Metabol Drug Interact.


83: Sosa-Macías M, Lazalde-Ramos BP, Galaviz-Hernández C, Rangel-Villalobos H,

Salazar-Flores J, Martínez-Sevilla VM, Martínez-Fierro ML, Dorado P, Wong ML,

Licinio J, LLerena A. Influence of admixture components on CYP2C9*2 allele

frequency in eight indigenous populations from Northwest Mexico. Pharmacogenomics

J. 2013 Dec;13(6):567-72. doi: 10.1038/tpj.2012.52. Epub 2013 Jan 29. PubMed

PMID: 23358499.

84: Llerena A, Berecz R, Peñas-Lledó E, Süveges A, Fariñas H. Pharmacogenetics of

clinical response to risperidone. Pharmacogenomics. 2013 Jan;14(2):177-94. doi:

10.2217/pgs.12.201. Review. PubMed PMID: 23327578.

85: López M, Dorado P, Ortega A, Peñas-Lledó E, Monroy N, Silva-Zolezzi I,



Cobaleda J, Gallego-Aguilera A, Alonso ME, Llerena A. Interethnic differences in

UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Mol

Biol Rep. 2013 Apr;40(4):3187-92. doi: 10.1007/s11033-012-2393-2. Epub 2013 Jan

1. PubMed PMID: 23277392.

86: Bernardo M, Bioque M, Parellada M, Saiz Ruiz J, Cuesta MJ, Llerena A, Sanjuán

J, Castro-Fornieles J, Arango C, Cabrera B; PEPs Group. Assessing clinical and

functional outcomes in a gene-environment interaction study in first episode of

psychosis (PEPs). Rev Psiquiatr Salud Ment. 2013 Jan-Mar;6(1):4-16. doi:

10.1016/j.rpsm.2012.11.001. Epub 2012 Dec 1. English, Spanish. PubMed PMID:

23206389.

87: Mas S, Llerena A, Saíz J, Bernardo M, Lafuente A. Strengths and weaknesses of

pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs

study. Pharmacogenomics. 2012 Nov;13(15):1773-82. doi: 10.2217/pgs.12.159.

Review. PubMed PMID: 23171340.

88: Dorado P, Beltrán LJ, Machín E, Peñas-Lledó EM, Terán E, Llerena A; CEIBA.FP

Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics

RIBEF. Losartan hydroxylation phenotype in an Ecuadorian population: influence of

CYP2C9 genetic polymorphism, habits and gender. Pharmacogenomics. 2012

Nov;13(15):1711-7. doi: 10.2217/pgs.12.160. PubMed PMID: 23171336.

89: Dorado P, Machín E, de Andrés F, Naranjo ME, Peñas-Lledó EM, Llerena A;

CEIBA.FP Consortium for the Ibero-American Network of Pharmacogenomics RIBEF.

Development of a HPLC method for the determination of losartan urinary metabolic

ratio to be used for the determination of CYP2C9 hydroxylation phenotypes. Drug

Metabol Drug Interact. 2012;27(4):217-33. PubMed PMID: 23093260.

90: Dorado P, de Andrés F, Naranjo ME, Peñas-Lledó EM, González I, González AP,

de la Rubia A, Llerena A. High-performance liquid chromatography method using

ultraviolet detection for the quantification of aripiprazole and

dehydroaripiprazole in psychiatric patients. Drug Metabol Drug Interact.


91: González-Vacarezza N, Abad-Santos F, Carcas-Sansuan A, Dorado P, Peñas-Lledó

E, Estévez-Carrizo F, Llerena A. Use of pharmacogenetics in bioequivalence

studies to reduce sample size: an example with mirtazapine and CYP2D6.

Pharmacogenomics J. 2013 Oct;13(5):452-5. doi: 10.1038/tpj.2012.29. Epub 2012 Jun

26. PubMed PMID: 22733239.

92: Peñas-Lledó EM, Trejo HD, Dorado P, Ortega A, Jung H, Alonso E, Naranjo ME,

López-López M, Llerena A. CYP2D6 ultrarapid metabolism and early dropout from

fluoxetine or amitriptyline monotherapy treatment in major depressive patients.

Mol Psychiatry. 2013 Jan;18(1):8-9. doi: 10.1038/mp.2012.91. Epub 2012 Jun 26.


93: Rodeiro I, Remírez-Figueredo D, García-Mesa M, Dorado P, LLerena A; CEIBA.FP

Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics

RIBEF. Pharmacogenetics in Latin American populations: regulatory aspects,

application to herbal medicine, cardiovascular and psychiatric disorders. Drug

Metabol Drug Interact. 2012;27(1):57-60. doi: 10.1515/dmdi-2012-0006. PubMed

PMID: 22718626.

94: Dorado P, López-Torres E, Peñas-Lledó EM, Martínez-Antón J, Llerena A.

Neurological toxicity after phenytoin infusion in a pediatric patient with



epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.

Pharmacogenomics J. 2013 Aug;13(4):359-61. doi: 10.1038/tpj.2012.19. Epub 2012

May 29. PubMed PMID: 22641027.

95: Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo

C, Fernandez-Piqueras J, Llerena A, Abad-Santos F, Baca-García E, Dal-Ré R, Ayuso

C; Spanish Consortium of Pharmacogenetics Research in Schizophrenia. Association

of common genetic variants with risperidone adverse events in a Spanish

schizophrenic population. Pharmacogenomics J. 2013 Apr;13(2):197-204. doi:

10.1038/tpj.2011.57. Epub 2012 Jan 3. PubMed PMID: 22212732; PubMed Central

PMCID: PMC3619141.

96: Peñas-Lledó EM, Blasco-Fontecilla H, Dorado P, Vaquero-Lorenzo C, Baca-García

E, Llerena A. CYP2D6 and the severity of suicide attempts. Pharmacogenomics. 2012

Jan;13(2):179-84. doi: 10.2217/pgs.11.146. Epub 2011 Dec 5. PubMed PMID:

22141351.

97: Dorado P, Heras N, Machín E, Hernández F, Teran E, Llerena A. CYP2D6 genotype

and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur J

Clin Pharmacol. 2012 May;68(5):637-44. doi: 10.1007/s00228-011-1147-8. Epub 2011

Nov 15. PubMed PMID: 22083166.

98: Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Lopez-Rodriguez

R, Fernandez-Navarro P, Baca-García E, Fernandez-Piqueras J, Dal-Ré R,

Abad-Santos F, Llerena A, Ayuso C; Spanish Consortium of Pharmacogenetics

Research in Schizophrenia. ATA homozigosity in the IL-10 gene promoter is a risk

factor for schizophrenia in Spanish females: a case control study. BMC Med Genet.

2011 Jun 9;12:81. doi: 10.1186/1471-2350-12-81. PubMed PMID: 21658228; PubMed

Central PMCID: PMC3144450.

99: Manolopoulos VG, Dechairo B, Huriez A, Kühn A, Llerena A, van Schaik RH, Yeo

KT, Ragia G, Siest G. Pharmacogenomics and personalized medicine in clinical

practice. Pharmacogenomics. 2011 May;12(5):597-610. doi: 10.2217/pgs.11.14.


100: López M, Dorado P, Monroy N, Alonso ME, Jung-Cook H, Machín E, Peñas-Lledó

E, Llerena A. Pharmacogenetics of the antiepileptic drugs phenytoin and

lamotrigine. Drug Metabol Drug Interact. 2011;26(1):5-12. doi:

10.1515/DMDI.2011.008. Review. PubMed PMID: 21557672.

101: Llerena A, Dorado P, Peñas-Lledó EM. Relevance of CYP2D6 for risperidone

pharmacokinetics, pharmacodynamics and adverse reactions. Pharmacogenomics. 2011

Mar;12(3):311-3. doi: 10.2217/pgs.11.11. PubMed PMID: 21449670.

102: Peñas-Lledó EM, Dorado P, Agüera Z, Gratacós M, Estivill X, Fernández-Aranda

F, Llerena A. High risk of lifetime history of suicide attempts among CYP2D6

ultrarapid metabolizers with eating disorders. Mol Psychiatry. 2011

Jul;16(7):691-2. doi: 10.1038/mp.2011.5. Epub 2011 Feb 15. PubMed PMID: 21321564.

103: Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, Pérez

B, Calzadilla LR. CYP2D6 genotype and debrisoquine hydroxylation phenotype in

Cubans and Nicaraguans. Pharmacogenomics J. 2012 Apr;12(2):176-83. doi:

10.1038/tpj.2010.85. Epub 2010 Dec 7. PubMed PMID: 21135868.

104: Almoguera B, Riveiro-Alvarez R, Gomez-Dominguez B, Lopez-Rodriguez R, Dorado

P, Vaquero-Lorenzo C, Dal-Ré R, Fernandez-Piqueras J, Llerena A, Abad-Santos F,

Ayuso C. Evaluating a newly developed pharmacogenetic array: screening in a



Spanish population. Pharmacogenomics. 2010 Nov;11(11):1619-25. doi:

10.2217/pgs.10.131. PubMed PMID: 21121779.

105: Peñas-Lledó EM, Dorado P, Agüera Z, Gratacós M, Estivill X, Fernández-Aranda

F, Llerena A. CYP2D6 polymorphism in patients with eating disorders.

Pharmacogenomics J. 2012 Apr;12(2):173-5. doi: 10.1038/tpj.2010.78. Epub 2010 Sep

28. PubMed PMID: 20877302.

106: Sosa-Macías M, Dorado P, Alanis-Bañuelos RE, Llerena A, Lares-Asseff I.

Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a

gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and

mestizos. Pharmacology. 2010;86(1):30-6. doi: 10.1159/000314334. Epub 2010 Jun

30. PubMed PMID: 20588073.

107: Dorado P, Sosa-Macias MG, Peñas-Lledó EM, Alanis-Bañuelos RE, Wong ML,

Licinio J, Lares-Asseff I, Llerena A. CYP2C9 allele frequency differences between

populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards.

Pharmacogenomics J. 2011 Apr;11(2):108-12. doi: 10.1038/tpj.2010.29. Epub 2010

May 11. PubMed PMID: 20458343.

108: Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A. Relation between

CYP2D6 genotype, personality, neurocognition and overall psychopathology in

healthy volunteers. Pharmacogenomics. 2009 Jul;10(7):1111-20. doi:

10.2217/pgs.09.75. PubMed PMID: 19604084.

109: Dorado P, Peñas-LLedó EM, de la Rubia A, LLerena A. Relevance of CYP2D6

-1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in

psychiatric patients. Pharmacogenomics. 2009 Jul;10(7):1083-9. doi:

10.2217/pgs.09.57. PubMed PMID: 19604081.

110: Sánchez-Romero MA, Dorado P, Guarino E, Llerena A. Development of a new

genotyping assay for detection of the BDNF Val66Met polymorphism using

melting-curve analysis. Pharmacogenomics. 2009 Jun;10(6):989-95. doi:

10.2217/pgs.09.44. PubMed PMID: 19530966.

111: Rodríguez-Antona C, Gurwitz D, de Leon J, Llerena A, Kirchheiner J, de Mesa

EG, Ibarreta D. CYP2D6 genotyping for psychiatric patients treated with

risperidone: considerations for cost-effectiveness studies. Pharmacogenomics.

2009 Apr;10(4):685-99. doi: 10.2217/pgs.09.15. PubMed PMID: 19374522.

112: Llerena A, Dorado P, Peñas-Lledó EM. Pharmacogenetics of debrisoquine and

its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics. 2009

Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. Review. PubMed PMID: 19102711.

113: Dorado P, Cáceres M, Pozo-Guisado E, Wong ML, Licinio J, Llerena A.

Development of a PCR-based strategy for CYP2D6 genotyping including gene

multiplication of worldwide potential use. Biotechniques. 2005 Oct;39(10

Suppl):S571-4. doi: 10.2144/000112044. PubMed PMID: 18957039.

114: González I, Peñas-Lledó EM, Pérez B, Dorado P, Alvarez M, LLerena A.

Relation between CYP2D6 phenotype and genotype and personality in healthy

volunteers. Pharmacogenomics. 2008 Jul;9(7):833-40. doi:

10.2217/14622416.9.7.833. PubMed PMID: 18597648.

115: Dorado P, Cavaco I, Cáceres MC, Piedade R, Ribeiro V, Llerena A.

Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy

Spanish volunteers. Eur J Clin Pharmacol. 2008 Oct;64(10):967-70. doi:

10.1007/s00228-008-0508-4. Epub 2008 Jun 12. PubMed PMID: 18548238.



116: Peñas-Lledó EM, Loeb KL, Puerto R, Hildebrandt TB, Llerena A. Subtyping

undergraduate women along dietary restraint and negative affect. Appetite. 2008

Nov;51(3):727-30. doi: 10.1016/j.appet.2008.04.014. Epub 2008 Apr 22. PubMed

PMID: 18501473.

117: López-Torres E, Salomón J, Vicario F, Peñas-Lledó E, Dorado P, Llerena A.

Aripiprazole-induced parkinsonism and its association with dopamine and serotonin

receptor polymorphisms. J Clin Psychopharmacol. 2008 Jun;28(3):352-3. doi:

10.1097/JCP.0b013e318172757f. PubMed PMID: 18480698.

118: Wanden-Berthe C, Dos Reis MG, Llerena A, de Camino R, Miguel LJ.

[Ibero-American Program of Science and Technology for Development]. Rev Panam

Salud Publica. 2008 Mar;23(3):218-9. Spanish. PubMed PMID: 18397588.

119: Dorado P, Peñas-Lledó EM, Llerena A. CYP2D6 polymorphism: implications for

antipsychotic drug response, schizophrenia and personality traits.

Pharmacogenomics. 2007 Nov;8(11):1597-608. Review. PubMed PMID: 18034624.

120: González I, Pérez N, Peñas-LLedó EM, LLerena A, González I, de la Rubia A.

High risk of polydipsia and water intoxication in schizophrenia patients.

Schizophr Res. 2008 Feb;99(1-3):377-8. Epub 2007 Oct 25. PubMed PMID: 17964118.

121: Cáceres MC, Peñas-Lledó EM, de la Rubia A, Llerena A. Increased use of

second generation antipsychotic drugs in primary care: potential relevance for

hospitalizations in schizophrenia patients. Eur J Clin Pharmacol. 2008

Jan;64(1):73-6. Epub 2007 Oct 19. PubMed PMID: 17952424.

122: Dorado P, Peñas-Lledó EM, González AP, Cáceres MC, Cobaleda J, Llerena A.

Increased risk for major depression associated with the short allele of the

serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele.

Fundam Clin Pharmacol. 2007 Aug;21(4):451-3. PubMed PMID: 17635185.

123: Llerena A, Michel G, Jeannesson E, Wong S, Manolopoulos VG, Hockett RD,

Boubekeur K, Siest G, Beaune P, Haefliger C, Arnold HP, Junien C, Petrovic N,

Molloy R, Bekers O, Donnelly C, Arens HJ, Kaput J, McComb J. Third Santorini

conference pharmacogenomics workshop report: "Pharmacogenomics at the crossroads:

what else than good science will be needed for the field to become part of

Personalized Medicine?". Clin Chem Lab Med. 2007;45(7):843-50. PubMed PMID:

17617025.

124: Peñas-Lledó EM, Dorado P, Cáceres MC, de la Rubia A, Llerena A. Association

between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A)

gene and schizophrenia: relevance for treatment with antipsychotic drugs. Clin

Chem Lab Med. 2007;45(7):835-8. PubMed PMID: 17617023.

125: González I, Pérez B, Alvarez M, Dorado P, Llerena A. [Study of debrisoquine

hydroxylation polymorphism (CYP2D6) in the Cuban population compared to

Spaniards]. Med Clin (Barc). 2007 May 26;128(20):772-4. Spanish. PubMed PMID:

17568504.

126: Dorado P, Berecz R, Peñas-Lledó EM, de la Rubia A, Llerena A. No effect of

the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma

concentrations in psychiatric patients. Eur J Clin Pharmacol. 2007

May;63(5):527-8. Epub 2007 Mar 8. PubMed PMID: 17345072.

127: Llerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A. Low

frequency of CYP2D6 poor metabolizers among schizophrenia patients.

Pharmacogenomics J. 2007 Dec;7(6):408-10. Epub 2007 Feb 27. PubMed PMID:



17325735.

128: Dorado P, Berecz R, Peñas-Lledó EM, Llerena A. Antipsychotic drugs and QTc

prolongation: the potential role of CYP2D6 genetic polymorphism. Expert Opin Drug

Metab Toxicol. 2007 Feb;3(1):9-19. Review. PubMed PMID: 17269891.

129: Dorado P, Berecz R, Peñas-Lledó EM, Cáceres MC, Llerena A. Clinical

implications of CYP2D6 genetic polymorphism during treatment with antipsychotic

drugs. Curr Drug Targets. 2006 Dec;7(12):1671-80. Review. PubMed PMID: 17168842.

130: Llerena A, Licinio J. Hot topic: pharmacogenetic and pharmacogenomics. Curr

Drug Targets. 2006 Dec;7(12):1639-40. PubMed PMID: 17168838.

131: Dorado P, Cáceres MC, Pozo-Guisado E, Wong ML, Licinio J, Llerena A.

Development of a PCR-based strategy for CYP2D6 genotyping including gene

multiplication of worldwide potential use. Biotechniques. 2005 Oct;39(4):571-4.


132: Berecz R, Cáceres M, Szlivka A, Dorado P, Bartók E, Peñas-LLedó E, LLerena

A, Degrell I. Reduced completed suicide rate in Hungary from 1990 to 2001:

relation to suicide methods. J Affect Disord. 2005 Oct;88(2):235-8. PubMed PMID:

16122812.

133: Gurwitz D, Lunshof JE, Dedoussis G, Flordellis CS, Fuhr U, Kirchheiner J,

Licinio J, Llerena A, Manolopoulos VG, Sheffield LJ, Siest G, Torricelli F,

Vasiliou V, Wong S. Pharmacogenomics education: International Society of

Pharmacogenomics recommendations for medical, pharmaceutical, and health schools

deans of education. Pharmacogenomics J. 2005;5(4):221-5. PubMed PMID: 15852053.

134: Dorado P, Berecz R, Cáceres MC, González I, Cobaleda J, Llerena A.

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance

liquid chromatography: application to the evaluation of CYP2D6 genotype and

debrisoquine metabolic ratio relationship. Clin Chem Lab Med. 2005;43(3):275-9.


135: LLerena A, Dorado P, O'Kirwan F, Jepson R, Licinio J, Wong ML. Lower

frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards.

Pharmacogenomics J. 2004;4(6):403-6. PubMed PMID: 15452553.

136: Berecz R, Dorado P, De La Rubia A, Cáceres MC, Degrell I, LLerena A. The

role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical

relevance for drug interactions. Curr Drug Targets. 2004 Aug;5(6):573-9. Review.


137: Llerena A, Berecz R, Dorado P, de la Rubia A. QTc interval, CYP2D6 and

CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol. 2004

Jun;18(2):189-93. PubMed PMID: 15260906.

138: LLerena A, de la Rubia A, Berecz R, Dorado P. Relationship between

haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9

genotypes in psychiatric patients. Pharmacopsychiatry. 2004 Mar;37(2):69-73.


139: LLerena A, Dorado P, Berecz R, González AP, Peñas-LLedó EM. Effect of CYP2D6

and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during

steady-state conditions. Eur J Clin Pharmacol. 2004 Feb;59(12):869-73. Epub 2004

Jan 16. PubMed PMID: 14726986.

140: LLerena A, Berecz R, Dorado P, González AP, Peñas-LLedó EM, De La Rubia A.

CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenomics J.



2003;3(5):300-2. PubMed PMID: 14583800.

141: Dorado P, Berecz R, Cáceres MC, Conzález I, Llerena A. Reproducibility over

time of the urinary diclofenac/4'-OH diclofenac ratio among different CYP2C9

genotypes. Eur J Drug Metab Pharmacokinet. 2003 Jul-Sep;28(3):213-5. PubMed PMID:

14527094.

142: Dorado P, Berecz R, Cáceres MC, LLerena A. Analysis of diclofenac and its

metabolites by high-performance liquid chromatography: relevance of CYP2C9

genotypes in diclofenac urinary metabolic ratios. J Chromatogr B Analyt Technol

Biomed Life Sci. 2003 Jun 15;789(2):437-42. PubMed PMID: 12742136.

143: Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, LLerena A. CYP2C9

genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin

Pharmacol. 2003 Jul;59(3):221-5. Epub 2003 May 7. PubMed PMID: 12734606.

144: Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, LLerena A.

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking

and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003

May;59(1):45-50. Epub 2003 Mar 28. PubMed PMID: 12682803.

145: LLerena A, de la Rubia A, Peñas-Lledó EM, Diaz FJ, de Leon J. Schizophrenia

and tobacco smoking in a Spanish psychiatric hospital. Schizophr Res. 2003 Apr

1;60(2-3):313-7. PubMed PMID: 12591592.

146: Berecz R, LLerena A, de la Rubia A, Gómez J, Kellermann M, Dorado P, Degrell

I. Relationship between risperidone and 9-hydroxy-risperidone plasma

concentrations and CYP2D6 enzyme activity in psychiatric patients.

Pharmacopsychiatry. 2002 Nov;35(6):231-4. PubMed PMID: 12518271.

147: LLerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is

related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine

in patients. J Psychopharmacol. 2002 Dec;16(4):361-4. PubMed PMID: 12503836.

148: Berecz R, de la Rubia Martínez A, Norberto Gamero MJ, Gutiérrez Casares JR,

Glaub T, Degrell I, Llerena A. [Relationship between clozapine plasma levels and

withdrawal symptoms]. Actas Esp Psiquiatr. 2002 Nov-Dec;30(6):397-9. Spanish.


149: LLerena A, Berecz R, Dorado P, de la Garza CS, Norberto MJ, Cáceres M,

Gutiérrez JR. Determination of risperidone and 9-hydroxyrisperidone in human

plasma by liquid chromatography: application to the evaluation of CYP2D6 drug

interactions. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan

5;783(1):213-9. PubMed PMID: 12450541.

150: LLerena A, Dorado P, Berecz R, González A, Jesús Norberto M, de la Rubia A,

Cáceres M. Determination of fluoxetine and norfluoxetine in human plasma by

high-performance liquid chromatography with ultraviolet detection in psychiatric

patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5;783(1):25-31.


151: LLerena A, de la Rubia A, Peñas-Lledó EM, Diaz FJ, de Leon J. Schizophrenia

and tobacco smoking in a Spanish psychiatric hospital. Schizophr Res. 2002 Dec

1;58(2-3):323-7. Corrected and republished in: Schizophr Res. 2003 Apr

1;60(2-3):313-7. PubMed PMID: 12409173.

152: Llerena A, Cáceres MC, Peñas-LLedó EM. Schizophrenia stigma among medical

and nursing undergraduates. Eur Psychiatry. 2002 Sep;17(5):298-9. PubMed PMID:

12381503.



153: LLerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening and

debrisoquine metabolic ratio in psychiatric patients treated with oral

haloperidol monotherapy. Eur J Clin Pharmacol. 2002 Jun;58(3):223-24. PubMed

PMID: 12162273.

154: Norberto MJ, Martínez M, Cáceres MC, Llerena A. [Optimizing pharmacologic

therapy for the elderly]. Rev Enferm. 2001 Sep;24(9):70-4. Spanish. PubMed PMID:

12150127.

155: Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F,

Eliasson E, Dahl ML. Pharmacokinetics of losartan and its metabolite E-3174 in

relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002 Jan;71(1):89-98.


156: LLerena A, Berecz R, de la Rubia A, Fernández-Salguero P, Dorado P. Effect

of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric

patients with different CYP2D6 genotypes. Ther Drug Monit. 2001 Dec;23(6):616-20.


157: Llerena A, De la Rubia Martínez A, Peñas-Lledó EM. [Prevalence of polydipsia

and water intoxication in psychiatric inpatients]. Actas Esp Psiquiatr. 2001

Sep-Oct;29(5):299-303. Spanish. PubMed PMID: 11602086.

158: Llerena A, Berecz R, Norberto MJ, de la Rubia A. Determination of clozapine

and its N-desmethyl metabolite by high-performance liquid chromatography with

ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001 May

5;755(1-2):349-54. PubMed PMID: 11393724.

159: Norberto Gamero MJ, Martínez Alvarez M, Postigo Mota S, Llerena Ruiz A.

[Poisoning by organophosphate insecticides. Epidemiology and prevention]. Rev

Enferm. 2000 Dec;23(12):847-54. Spanish. PubMed PMID: 11221211.

160: Llerena A, Berecz R, de la Rubia A, Norberto MJ, Benítez J. Use of the

mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug

Monit. 2000 Aug;22(4):397-401. PubMed PMID: 10942178.

161: Postigo Mota S, Llerena Ruiz A, Lavado García JM, Norberto Gamero MJ, Durán

Gómez N. [Subcutaneous drug administration. Indications for the use in terminal

patients]. Rev Enferm. 1999 Dec;22(12):887-90. Review. Spanish. PubMed PMID:

10797775.

162: Berecz R, Glaub T, Kellermann M, de la Rubia A, Llerena A, Degrell I.

Clozapine withdrawal symptoms after change to sertindole in a schizophrenic

patient. Pharmacopsychiatry. 2000 Jan;33(1):42-4. PubMed PMID: 10721883.

163: Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JA, Berecz R, Duran M,

Benítez J. Pharmacokinetic interaction of fluvoxamine and thioridazine in

schizophrenic patients. J Clin Psychopharmacol. 1999 Dec;19(6):494-9. PubMed

PMID: 10587283.

164: Kiivet RA, Dahl ML, Llerena A, Maimets M, Wettermark B, Berecz R. Antibiotic

use in 3 European university hospitals. Scand J Infect Dis. 1998;30(3):277-80.


165: Martínez C, Agúndez JA, Olivera M, Llerena A, Ramirez R, Hernández M,

Benítez J. Influence of genetic admixture on polymorphisms of drug-metabolizing

enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic

population. Clin Pharmacol Ther. 1998 Jun;63(6):623-8. PubMed PMID: 9663176.

166: Agúndez JA, Ramirez R, Hernandez M, Llerena A, Benítez J. Molecular



heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from

Europe. Pharmacogenetics. 1997 Aug;7(4):337-40. PubMed PMID: 9295063.

167: Berecz R, Llerena A, Benitez J. [Interaction between prajmaline and

metoprotol: a possible pharmacogenetic explanation]. Orv Hetil. 1997 Apr

27;138(17):1097-8. Hungarian. PubMed PMID: 9182277.

168: Llerena A, Cobaleda J, Martínez C, Benítez J. Interethnic differences in

drug metabolism: influence of genetic and environmental factors on debrisoquine

hydroxylation phenotype. Eur J Drug Metab Pharmacokinet. 1996

Apr-Jun;21(2):129-38. Review. PubMed PMID: 8839686.

169: Kiivet RA, Llerena A, Dahl ML, Rootslane L, Sánchez Vega J, Eklundh T,

Sjöqvist F. Patterns of drug treatment of schizophrenic patients in Estonia,

Spain and Sweden. Br J Clin Pharmacol. 1995 Nov;40(5):467-76. PubMed PMID:


170: Llerena A, Ohman B, Alván G. References used in a drug information centre.

Eur J Clin Pharmacol. 1995;49(1-2):87-9. PubMed PMID: 8751027.

171: Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindström

L, Rodriguez de la Rubia I, Ramos S, Benitez J. Clozapine disposition covaries

with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol. 1994

Nov;38(5):471-3. PubMed PMID: 7893591; PubMed Central PMCID: PMC1364883.

172: Llerena A, Kiivet RA. Fixed combinations of neuroleptics with

antidepressants: potential risks and estimation of use. Br J Clin Pharmacol. 1994

Jun;37(6):531-2. PubMed PMID: 7917769; PubMed Central PMCID: PMC1364810.

173: Dahl ML, Llerena A, Bondesson U, Lindström L, Bertilsson L. Disposition of

clozapine in man: lack of association with debrisoquine and S-mephenytoin

hydroxylation polymorphisms. Br J Clin Pharmacol. 1994 Jan;37(1):71-4. PubMed


174: LLerena A, Herraíz AG, Cobaleda J, Johansson I, Dahl ML. Debrisoquin and

mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with

neuroleptic and antidepressant agents. Clin Pharmacol Ther. 1993

Dec;54(6):606-11. PubMed PMID: 7903915.

175: Llerena A, Valdivielso MJ, Benítez J, Bertilsson L. Reproducibility over

time of mephenytoin and debrisoquine hydroxylation phenotypes. Pharmacol Toxicol.

1993 Jul;73(1):46-8. PubMed PMID: 8234192.

176: Llerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L.

Relationship between personality and debrisoquine hydroxylation capacity.

Suggestion of an endogenous neuroactive substrate or product of the cytochrome

P4502D6. Acta Psychiatr Scand. 1993 Jan;87(1):23-8. PubMed PMID: 8424321.

177: Reviriego J, Bertilsson L, Carrillo JA, Llerena A, Valdivielso MJ, Benítez

J. Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects

compared to other Caucasian populations. Eur J Clin Pharmacol. 1993;44(6):593-5.


178: Bertilsson L, Dahl ML, Ekqvist B, Llerena A. Disposition of the neuroleptics

perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic

debrisoquine hydroxylation. Psychopharmacol Ser. 1993;10:230-7. Review. PubMed

PMID: 8103225.

179: Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is

dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of



the reduced metabolite in poor metabolizers. Ther Drug Monit. 1992

Jun;14(3):261-4. PubMed PMID: 1412613.

180: Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition

is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit. 1992

Apr;14(2):92-7. PubMed PMID: 1585408.

181: Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Genetic factors in the

metabolism of haloperidol. Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:84A-85A.


182: Laredo Quesada JM, Jara Sánchez C, Benítez Rodríguez J, Fernández Gundín MJ,

Vargas Castrillón E, Muñoz González JJ, Llerena Ruiz A, Cobaleda Polo J,

Pérez-Manga G. [Acetylation polymorphism in lung cancer]. An Med Interna. 1991

Feb;8(2):66-8. Spanish. PubMed PMID: 1893005.

183: Ladero JM, Benítez J, Jara C, Llerena A, Valdivielso MJ, Muñoz JJ, Vargas E.

Polymorphic oxidation of debrisoquine in women with breast cancer. Oncology.

1991;48(2):107-10. PubMed PMID: 1997931.

184: Benítez J, Ladero JM, Jara C, Carrillo JA, Cobaleda J, Llerena A, Vargas E,

Muñoz JJ. Polymorphic oxidation of debrisoquine in lung cancer patients. Eur J

Cancer. 1991;27(2):158-61. PubMed PMID: 1827280.

185: Benítez J, Ladero JM, Fernández-Gundín MJ, Llerena A, Cobaleda J, Martínez

C, Muñoz JJ, Vargas E, Prados J, González-Rozas F, et al. Polymorphic oxidation

of debrisoquine in bladder cancer. Ann Med. 1990 Jun;22(3):157-60. PubMed PMID:

2393550.

186: Benitez J, Ladero JM, Jimenez-Jimenez FJ, Martinez C, Puerto AM, Valdivielso

MJ, Llerena A, Cobaleda J, Muñoz JJ. Oxidative polymorphism of debrisoquine in

Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Apr;53(4):289-92. PubMed


187: Llerena A, Cobaleda J, Benítez J. Debrisoquine hydroxylation phenotypes in

healthy volunteers. Lancet. 1989 Jun 17;1(8651):1398. PubMed PMID: 2567421.

188: Henthorn TK, Benitez J, Avram MJ, Martinez C, Llerena A, Cobaleda J, Krejcie

TC, Gibbons RD. Assessment of the debrisoquin and dextromethorphan phenotyping

tests by gaussian mixture distributions analysis. Clin Pharmacol Ther. 1989

Mar;45(3):328-33. PubMed PMID: 2920506.

189: Ladero JM, Jimenez FJ, Benitez J, Fernandez-Gundin MJ, Martinez C, Llerena

A, Cobaleda J, Muñoz JJ. Acetylator polymorphism in Parkinson's disease. Eur J

Clin Pharmacol. 1989;37(4):391-3. PubMed PMID: 2598972.

190: Benítez J, Piñas B, García MA, Martínez C, Llerena A, Cobaleda J.

Debrisoquine oxidation phenotype in psychiatric patients. Psychopharmacol Ser.

1989;7:206-10. PubMed PMID: 2594729.

191: Spina E, Buemi AL, Caputi AP, Benitez J, Cobaleda J, Garcia MA, Llerena A,

Piña B. Debrisoquine oxidation in schizophrenic patients treated with

neuroleptics. Pharmacol Res Commun. 1988 Dec;20(12):1103-4. PubMed PMID: 2905478.

192: Benítez J, LLerena A, Cobaleda J. Debrisoquin oxidation polymorphism in a

Spanish population. Clin Pharmacol Ther. 1988 Jul;44(1):74-7. PubMed PMID:

3391005.

193: Muñoz Sanz A, Llerena A, Jiménez M, Sáenz de Santamaría FJ. [Hepatic

actinomycosis]. Rev Clin Esp. 1985 Dec;177(9):476. Spanish. PubMed PMID: 4095324.



Projects PRINCIPAL INVESTIGATOR

1. PROJECT TITLE: Comparison of the use of medicines.

FINANCIAL ENTITY: European Union. DGXII. Unión Europea ERB 3510 PL 927025.

LENGHT, FROM-TO: 1993 - 1993

2. PROJECT TITLE: Estudio de la esquizofrenia en Extremadura. Análisis de factores farmacoepidemiológicos, clínicos y psicosociales.

FINANCIAL ENTITY: Junta de Extrermadura. Acciones preparatorias para el Plan Regional de Investigación. PRI97-D081

LENGHT, FROM-TO: 1997 - 1999.

3. PROJECT TITLE: Desarrollo de Unidad para estudios farmacoepidemiológicos.

FINANCIAL ENTITY: Junta de Extremadura. Consejería de Bienestar Social. PRI97- BS27


4. PROJECT TITLE: Estudio de la intoxicación acuosa en pacientes psiquiátricos.

FINANCIAL ENTITY: Junta de Extremadura. Consejería de Bienestar Social. PRI97- BS26


5. PROJECT TITLE: Pharmacogenetic of antipsychotic drugs.

FINANCIAL ENTITY: Ministerio de Asuntos Exteriores. VIII Comisión Mixta de Cooperación Científico-Técnica entre España y Hungría. E-2/97.


6. PROJECT TITLE: Treatment of schizophrenic: evaluation of cost and efficacy in four european countries: Spain, Estonia, Hungary and Sweden. ERBIC15 CT98 0340

FINANCIAL ENTITY: Unión Europea. DG XII.

LENGHT, FROM-TO: 1998-2001.

PRINCIPAL INVESTIGATOR: Adrián LLerena (Spain, Coordinator), Raul A. Kiivet (Estonia), Marja-Liisa Dahl (Sweden), Itsván Degrell (Hungary).

7. PROJECT TITLE: Estudio farmacogenético de poblaciones iberoamericanas: análisis comparativo con la población extremeña.

FINANCIAL ENTITY: Junta de Extremadura. Fondo Social Europeo.


8. PROJECT TITLE: Factores de Riesgo y evaluación del tratamiento farmacológico de la esquizofrenia en Extremadura.

FINANCIAL ENTITY: Junta de Extremadura. Fondo Social Europeo. I PRI99- C019

LENGHT, FROM-TO: 2000.

9. PROJECT TITLE: Estudio evolutivo de la utilización de fármacos en Extremadura (1990-2000).

FINANCIAL ENTITY: Junta de Extremadura. Consejería de Sanidad y Consumo. CS00-0042


10. PROJECT TITLE: Estudio evolutivo del tratamiento farmacológico de la esquizofrenia en Extremadura.

Fuente: Junta de Extremadura. Fondo Social Europeo. I PRI00- C036

LENGHT, FROM-TO: 2001-2002.

11. PROJECT TITLE: Farmacogenetica del CYP2C9 en la Población Española: Implicaciones Clínicas

FINANCIAL ENTITY: Ministerio de Sanidad y Consumo. Instituto Carlos III. Fondo de Investigación Sanitaria. FIS 01-0699


12. PROJECT TITLE: Estudio evolutivo de la utilización de fármacos en Extremadura (1990-2000). 2ªAnualidad.





13. PROJECT TITLE: Estudios farmacogenéticos y clínicos en pacientes psiquiátricos

FINANCIAL ENTITY: Ministerio de Asuntos Exteriores. IX Comisión Mixta de Cooperación Científico-Técnica entre España y Hungría. S&T E-01/42.


14. PROJECT TITLE: Factores farmacogenéticos influyentes en la cardiotoxicidad de fármacos antipsicóticos



15. PROJECT TITLE: Factores farmacogenéticos influyentes en la cardiotoxicidad de fármacos antipsicóticos 2

FINANCIAL ENTITY: Junta de Extremadura. Consejería de Sanidad y Consumo. SAN03-016


17. PROJECT TITLE: CYP2D6 Y CYP2C9: VARIABILIDAD INTERÉTNICA Y RELACIÓN CON LA PERSONALIDAD

FINANCIAL ENTITY: Ministerio de Ciencia y Tecnología. Proyectos de Investigación Científica y Desarrollo Tecnológico. SAF2003.05716

LENGHT, FROM-TO: 2003-2004

18. PROJECT TITLE: Factores genéticos y ambientales predisponentes al alargamiento QTc en pacientes en tratamiento

FINANCIAL ENTITY: Junta de Extremadura. Consejería de Sanidad y Consumo. S.SS04.36

LENGHT, FROM-TO: 2005

19. PROJECT TITLE: Farmacogenética y farmacoepidemiologia de la esquizofrenia en Extremadura

FINANCIAL ENTITY: Junta de Extremadura. Consejería de Sanidad y Consumo. S.CURM04.11


20. PROJECT TITLE: Factores genéticos y ambientales predisponentes al alargamiento del espacio QTc en pacientes en tratamiento.

FINANCIAL ENTITY: Junta de Extremadura. Consejería de Sanidad y Consumo. S.SS05.75.


21. PROJECT TITLE: Red Iberoamericana de Farmacogenética y Farmacogenómica: Impacto en Salud Pública.

FINANCIAL ENTITY: CYTED. Programa Iberoamericano de Ciencia y Tecnología para el Desarrollo. 206RT0290


22. PROJECT TITLE: Estudio de la esquizofrenia en la provincia de Badajoz en el contexto extemeñoe internacional.

FINANCIAL ENTITY: Diputación Provincial de Badajoz. Convocatoria pública de subvenciones destinadas a tares de investigación y estudios de interes provincial 2006.


23. PROJECT TITLE: Farmacogenética de la esclerosis múltiple y su asociación con la depresión

FINANCIAL ENTITY: Junta de Extremadura. Consejería de Sanidad y Consumo. S.SS06.--.


24. PROJECT TITLE: Relevance of genetic factors in the clinical response to aripiprazol in schizophrenic patients.

FINANCIAL ENTITY: Ministerio de Ciencia y Tecnología. Plan Nacional de I+D+I. SAF2006-13589


25. PROJECT TITLE: Farmacogenética de la depresión y de la respuesta a fármacos antidepresivos en Asistencia Primaria.

FINANCIAL ENTITY: Ministerio de Sanidad y Consumo, Instituto Carlos III, Fondo de Investigación Sanitaria. PI061681


26. PROJECT TITLE: Estudio del Polimorfismo genético de relevancia para estrategias de medicina



personalizada en Esclerosis Múltiple

FINANCIAL ENTITY: Junta de Extremadura. Consejería de Sanidad y Consumo. S.SS07.03


27. PROJECT TITLE: Utilidad de la Farmacogenética para predecir la eficacia y la seguridad de risperidona y otros antipsicóticos atípicos

FINANCIAL ENTITY: Ministerio de Sanidad y Consumo, Instituto Carlos III, Fondo de Investigación Sanitaria. EC07/90604


28. PROJECT TITLE: Farmacogenética de Poblaciones Mestizas e Indígenas Mexicanas (Ibero Americanas)

FINANCIAL ENTITY: Junta de Extremadura - RIBEF-SIFF


29. PROJECT TITLE: Red Iberoamericana de Farmacologia, Productos Biológicos y Plantas Naturales

FINANCIAL ENTITY: Junta de Extremadura- RIBEF-SIFF


30. PROJECT TITLE: Farmacogenetica de efectos adversos de fármacos antidepresivos

FINANCIAL ENTITY: Ministerio de Sanidad y Consumo, Instituto Carlos III, Fondo de Investigación Sanitaria.


31. PROJECT TITLE: MESTIFAR Mestizaje, Salud y Fármacogenética en Iberoamérica

FINANCIAL ENTITY: Junta de Extremadura- RIBEF-SIFF


32. PROJECT TITLE: Implementation of Personalized Medicine for Health Care Services and Clinical Research MEDEA

FINANCIAL ENTITY: European Union, Spanish Government, Extremadura Government and University.


Memberships SCIENTIFIC SOCIETIES

SEFF Spanish Society for Pharmacogenetics and Pharmacogenomics (Vicepresident 2015- current)

SEFC Spanish Society of Clinical Pharmacology Vicepresident (2013-2015)

IUPHAR Pharmacogenetics Coommitee Member (2009- current)

ASCPT American Society for Clinical Pharmacology and Therapeutics (2012-)

ESPT European Society of Pharmacogenomics and Theranostics (co-founder) Vicepresident (2010-2013) and Board Member (2010-current)

EDITORIAL BOARD MEMBER:

Editor/Associate Editor

- Current Pharmacogenomics and Personalize Medicine (Chief Editor 2013-)

- Drug Metabolism and Drug Interactions (Board Member 2011-15 Editor in Chief 2015-)

- Journal of Pharmacogenomics and Pharmacoproteomics (Executive Editor 2012-)

- Clinical Therapeutics (Board of International Consulting Editors 2014-)

- The Pharmacogenomics Journal (Section Editor 2015-)

Board Member

- The Pharmacogenomics Journal

- Pharmacogenomics

- Current Clinical Pharmacology

- Frontiers in Pharmacogenetics and Pharmacogenomics

- Pharmacogenomics and Pharmacoproteomics



- SCIENTIFIC AWARDS

LATINFARMA Association of Latinoamerican Societies of Pharmacology October 2013

- INTERNATIONAL SCIENTIFIC TALKS AND CONFERENCES

NORTHAMERICA: - California, Florida, NY, North Caroline, Washington (US); Toronto, Quebec (Canada);

LATINAMERICA- Monterrey, Durango, Chihuahua, Guadalajara, Guanajuato, León, Puerto Vallarta, Veracruz, Xochimilco, DF, Tuxla-Gutierrez, Mexico DF, Mazatlan, Mérida (Mexico), Copán (Honduras), León, Managua (Nicaragua), San José (Costa Rica), Panamá (Panamá), La Habana, Cárdenas (Cuba), Bogotá, Cartagena de Indias (Colombia), Quito, Guayaquil (Ecuador), Lima (Perú),Santiago, Concepción (Chile), Buenos Aires (Argentina), Montevideo (Uruguay), Porto Alegre, Sao Paulo, Rio de Janeiro, Caxias do Sul, Aguas de Lindoia, Belo Horizonte, Joao Pessoa (Brasil); San Juan (Puerto Rico); Guatemala (Guatemala); El Salvador (El Salvador)

AFRICA-MIDDLE EAST- Marrakesh (Marruecos); Tel-Aviv, Jerusalem (Israel), Cape Town (South Africa), Istambul (Turkey)

ASIAPACIFIC - Beiging, (China); Cristchurch (Nueva Zelanda); Camberra, Sidney (Australia),Singapur (Singapur), New Dehli (India)

EUROPE (except Spain)- Algarve-Vilamoura, Faro, Coimbra, Lisboa, Porto, Covilha, Evora (Portugal), Verona, Roma, Erice, Taromina (Italia); Nice (Francia); Bruxelles, Anterp (Belgica), London,Oxford, Edimbourg (UK); Lund, Estocolmo, Upssala (Suecia); Tallin, Tartu (Estonia), Heidelberg (Alemania), Salzburg (Austria), Geneve (Suiza), Aarhus, Copenhague (Dinamarca), Budapest, Debrecen (Hugria) Dubronik (Croacia), Bled (Eslovenia), Alexandroupulis, Thira (Grecia), Rotterdam (Holland), etc

Other Relevant Information ACADEMIC POSITIONS:

- Vicedean Extremadura University Medical School (2001)

- Director of Rectorate Office for International Development Cooperation. University of Extremadura, Spain (2001-2008)

NETWORKS:

- Coordinator and founder. Iberoamerican Network of Pharmacogenetics and Pharmacogenomics www.ribef.com (2006-current)

- CIBERSAM Spanish Network for Research in Mental Health

- CAIBER Spanish Network for Clinical Research -

- SCREN Spanish Clinical Research Network (affiliated to European ECRIN)

ADVISOR AND CONSULTANCY:

- EU- IPTS Institute For Prospective Technology. European Union (2007-2009)

- CTAIC. Comisión Técnica de Apoyo a la Investigación Clínica. Ministerio de Sanidad. Spanish Goverment 2013

- CACYTEX Consejo Asesor de Ciencia y Tecnología Gobierno de Extremadura (Spain) 2013-current

- WHO/Geneva. 2009/2011.

- OPS/PAHO Washington 2013.

- CIOMS Geneva (2017- current)


PERSONAL INFORMATION Adrian Llerena Ruiz Faculty of ... · PDF fileCurriculum vitae Adrian...

Documents

Transcript of PERSONAL INFORMATION Adrian Llerena Ruiz Faculty of ... · PDF fileCurriculum vitae Adrian...